US 12,220,433 B2
Methods of generating, repairing and/or maintaining connective tissue in vivo
Peter Ghosh, Fairlight (AU)
Assigned to MESOBLAST, INC., New York, NY (US)
Filed by Mesoblast, Inc., New York, NY (US)
Filed on Jul. 26, 2022, as Appl. No. 17/873,504.
Application 15/177,708 is a division of application No. 12/452,767, granted, now 9,381,216, issued on Jul. 5, 2016, previously published as PCT/AU2008/001137, filed on Aug. 6, 2008.
Application 17/873,504 is a continuation of application No. 16/585,911, filed on Sep. 27, 2019, abandoned.
Application 16/585,911 is a continuation of application No. 15/177,708, filed on Jun. 9, 2016, abandoned.
Claims priority of provisional application 61/133,111, filed on Jun. 25, 2008.
Claims priority of application No. 2007904212 (AU), filed on Aug. 6, 2007.
Prior Publication US 2022/0354902 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/545 (2015.01); A61K 9/48 (2006.01); A61K 31/726 (2006.01); A61K 31/727 (2006.01); A61K 31/728 (2006.01); A61K 31/737 (2006.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 38/14 (2006.01); A61K 47/36 (2006.01); A61L 27/38 (2006.01); A61L 27/52 (2006.01); C12N 5/0775 (2010.01)
CPC A61K 35/545 (2013.01) [A61K 9/4866 (2013.01); A61K 31/726 (2013.01); A61K 31/727 (2013.01); A61K 31/728 (2013.01); A61K 31/737 (2013.01); A61K 35/12 (2013.01); A61K 35/28 (2013.01); A61K 38/14 (2013.01); A61K 47/36 (2013.01); A61L 27/3834 (2013.01); A61L 27/3856 (2013.01); A61L 27/52 (2013.01); C12N 5/0663 (2013.01); A61K 2035/124 (2013.01); A61K 2300/00 (2013.01); A61L 2430/38 (2013.01); C12N 2501/905 (2013.01)] 9 Claims
 
1. A method of treating a disease in a human subject arising from degradation and/or inflammation of an avascular connective tissue that is rich in proteoglycans, comprising administering to the human subject a population of allogenic cells enriched for STRO-1+, tissue nonspecific alkaline phosphatase (TNAP)+multipotential precursor cells or progeny cells thereof, or both such cells,
a. wherein paracrine activities of the administered population of allogenic cells enriched for STRO-1+, TNAP+multipotential precursor cells or progeny cells thereof protect or stimulate growth or regeneration of the connective tissue that is rich in proteoglycans, or both,
b. wherein the disease is selected from the group consisting of tendonitis, back pain, rotary cuff tendon degradation, Carpal tunnel syndrome, De Quervain's syndrome, degenerative cervical and/or lumbar discs, intersection syndrome, reflex sympathetic dystrophy syndrome (RSDS), stenosing tenosynovitis, epicondylitis, tenosynovitis, thoracic outlet syndrome, ulnar nerve entrapment, radial tunnel syndrome, repetitive strain injury (RSI), osteoarthritis, rheumatoid arthritis, psoriatic arthritis, seronegative arthritis, arthritis associated with inflammatory bowel disease, ankylosing spondylitis, and a degenerated intervertebral disc disorder, and
c. wherein the population of allogeneic cells enriched for STRO-1+, tissue nonspecific alkaline phosphatase (TNAP)+multipotential precursor cells is, or progeny cells thereof are, or both are administered to a joint space.